Strategic decisions on assets are typically made in silos over months to years. We change that. AssetOS is a reasoning and synthesis software platform optimising your asset decisions as new evidence lands.
Indication strategy
Gout, heart failure or Parkinson’s?
Compare the evidence required to advance an NLRP3 inhibitor in each indication.
Feasibility & safety
What exposure does each indication require?
Distinguish short-course, chronic and CNS exposure requirements for the candidate.
Development plan
Which study would change the lead indication?
Order the studies around the evidence missing from each indication path.
Clinical & regulatory strategy
What would establish proof of concept?
Connect pain, cardiac function and CNS readouts to their respective clinical questions.
Competition & market
Where could NLRP3 inhibition offer an advantage?
Compare the proposed benefit with current care and competing NLRP3 programs.
IP & FTO screening
Which claims constrain an NLRP3 inhibitor?
Potential blocking claims identified for counsel's review.
Partnering & licensing
Who could advance the selected indication?
Potential partners and licensing routes matched to the asset's stage and evidence.
Go/no-go
What evidence justifies the next investment?
The case for advancing, unresolved risks and findings that could change the decision.
Indication strategyComparison in progress
Feasibility & safetyCNS exposure unresolved
Development plan3 studies in progress
Clinical & regulatory strategy
Competition & market
IP & FTO screening
Partnering & licensing
Go/no-goAwaiting readouts
Acute flare
Insufficient pain benefit → deprioritise gout.
HFrEF
Biomarker change without functional benefit → reassess the clinical rationale.
CNS
Inadequate brain exposure → close this candidate’s CNS path.
Dose-ranging design · Review needed
Connect development planning, regulatory strategy, IP and partnering decisions. Keep the plan current as new evidence changes the asset’s risks and opportunities.
Keep the development plan current.
AssetOS tracks new findings, flags changes in risk and proposes updates to the development plan.
Bring relevant evidence together.
Draw on scientific literature, trial results, regulatory reviews, patents and company disclosures.
See the rationale behind each recommendation.
See how evidence is weighed, where uncertainty remains and what would change the recommendation.
Trace each conclusion to its source.
Follow citations to the original records and see the evidence cutoff used for the assessment.
Under every plan sit our causal disease models. Each conclusion they hand the dossier is a causal graph with a citation on every arrow.
We’ll walk through your development plan together and show you where AssetOS can help.